Ariad to reduce initial dose in mid-stage trial of lung cancer drug – Boston Business Journal (blog)

by lowes1 on September 30, 2013

Ariad to reduce initial dose in mid-stage trial of lung cancer drug
Boston Business Journal (blog)
Shares in Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) dipped 3 percent Monday after the company said it will reduce the initial recommended dose of its potential drug to treat non-small cell lung cancer (NSCLC) in a planned Phase 2 trial. The company 
ARIAD Pharma (ARIA) Updates on AP26113; Will Start at Lower Dose to Lessen StreetInsider.com (subscription)
Novartis AG (ADR) (NVS): Ariad trades lower after AP26113 news despite Seeking Alpha

all 9 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: